U.S., Oct. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07882017) titled 'Tenapanor in Maintenance Hemodialysis Patients' on April 21.
Brief Summary: The investigators hypothesize that Tenapanor can improve serum phosphorus control and regulate intestinal metabolism in maintenance hemodialysis patients without increasing the risk of severe gastrointestinal adverse events. Therefore, this study intends to take maintenance hemodialysis patients with hyperphosphatemia as the research object, prospectively observe patients receiving Tenapanor as part of their routine care, and clarify the real-world efficacy of Tenapanor for phosphorus management and its impact on intestinal metabolism in these patients.
Stu...